TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00250926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
Study: NCT00854750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: SQ weekly injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: SQ weekly injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR
Description: SQ weekly injection
Study: NCT04252144

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dietary assessment
Description: Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary assessment
Description: Dietary assessment is not within standards of care for patients with gastroesophageal reflux disease in Russia. Subjects enrolled to the study are to be interviewed on most common foods consumption in terms of frequency of use and sizes of portions.
Study: NCT04524884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study: NCT03444753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986299
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986299
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day
Study: NCT00354458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rolofylline
Description: rolofylline 30 mg IV QD; 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: rolofylline Pbo 30 mg IV QD; 3 days
Study: NCT03075007

Intervention type: RADIATION
Intervention: Florbetaben F18
Description: 10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.

Intervention type: PROCEDURE
Intervention: Transcranial Doppler
Description: All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
Study: NCT02088346

Intervention type: OTHER
Intervention: Telemedicine consultation system
Description: Telemedicine consultation system based on portable hardwares
Study: NCT02386709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
Study: NCT01360060

Intervention type: DRUG
Intervention: Magnesium Sulphate
Description: Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
Study: NCT04217928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Debridement
Description: Arthroscopic debridement will be performed under portal site local anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Hemi-Trapeziectomy with Mini TightRope
Description: Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
Study: NCT02147353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinecatechins 15% Ointment
Description: Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy alone
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy alone
Description: Cryotherapy will be standardized in all subjects and for all treated lesions.
Study: NCT01759368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring assisted self-care
Description: Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
Study: NCT02145247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: 3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: 3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours.
Study: NCT02789527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: DNA sampling from a saliva sample

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: DNA sampling from a saliva sample

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: DNA sampling from a saliva sample

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: DNA sampling from a saliva sample
Study: NCT00899548

Intervention type: GENETIC
Intervention: DNA methylation analysis
Description: laboratory analysis
Study: NCT03997188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepilor
Description: ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hepilor
Description: ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
Study: NCT03513159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathfinder support
Description: A pathfinder will support the patient with structured activities.
Study: NCT00631072

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: INKT
Description: Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
Study: NCT00899548

Intervention type: GENETIC
Intervention: microarray analysis
Description: laboratory analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: laboratory analysis
Study: NCT00089752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) Treatment
Description: CPAP device used at night

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP device - CPAP device with pressure delivered <1 cm H20
Description: Sham CPAP device used at night
Study: NCT02948127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID cp ΔM2-2 Vaccine
Description: 10\^5 plaque-forming units (PFUs); administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as nose drops
Study: NCT03367793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Clinically Derived
Description: Prescription spectacle lenses determined by clinically derived techniques. The specific techniques employed for each subject are left up to the masked examiner and are dependent upon the information needed for refraction determination, as well as ability of the participant to cooperate for testing. Measures may include autorefraction obtained pre or post dilation, retinoscopy obtained pre or post dilation, and subjective refraction obtained pre or post dilation.
Study: NCT00899548

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: laboratory analysis
Study: NCT01393327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
Study: NCT03533985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Song of Kin
Description: Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gato box
Description: Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocean disc
Description: Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent singing
Description: Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tonal Vocal holding
Description: Music therapist will provide a vowel, long held tone, sung without vibrato

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muted shaker
Description: If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
Study: NCT02838771

Intervention type: OTHER
Group type: OTHER
Intervention: Water drinking test
Description: Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water drinking test
Description: Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.

Intervention type: OTHER
Group type: OTHER
Intervention: Dysphagia screening questionnaire
Description: Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
Study: NCT03367793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Metric Technique #2 Derived
Description: Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Metric Technique #2 Derived
Description: Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles - Metric Technique #2 Derived
Description: Prescription spectacle lenses determined by metric-derived objective technique #2. For this method, wavefront error will be measured with the COAS (complete ophthalmic analysis system) wavefront aberrometer post-dilation with the goal of obtaining 3 to 5 high quality captures per eye. Wavefront measures will be re-sized to the patient's habitual pupil diameter and averaged. Post-measurement analysis will then be performed using a computer algorithm to identify the refractive correction predicted to produce the best image quality, as measured by maximization of the image quality metric Pupil Fraction tessellated (PFSt). The refractive correction determined from this analysis will be produced in prescription spectacle lenses and dispensed to the patient as the Intervention: Spectacles - Metric Technique #2 Derived.
Study: NCT01928212

Intervention type: DEVICE
Intervention: Optical coherence tomography

Intervention type: DEVICE
Intervention: Optical coherence tomography
Study: NCT02838771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dysphagia screening questionnaire
Description: Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
Study: NCT02670031

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance
Description: For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.

Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.

Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.

Intervention type: OTHER
Intervention: Echocardiogram
Description: For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.

Intervention type: OTHER
Intervention: Electrocardiogram
Description: To examine specific function of the heart.

Intervention type: OTHER
Intervention: Electrocardiogram
Description: To examine specific function of the heart.

Intervention type: OTHER
Intervention: Electrocardiogram
Description: To examine specific function of the heart.

Intervention type: DEVICE
Intervention: Ambulatory Blood Pressure Monitoring
Description: A 24-hour test.

Intervention type: DEVICE
Intervention: Ambulatory Blood Pressure Monitoring
Description: A 24-hour test.

Intervention type: DEVICE
Intervention: Ambulatory Blood Pressure Monitoring
Description: A 24-hour test.

Intervention type: OTHER
Intervention: Retinal Photography (Optional)
Description: The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.

Intervention type: OTHER
Intervention: Retinal Photography (Optional)
Description: The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.

Intervention type: OTHER
Intervention: Retinal Photography (Optional)
Description: The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
Study: NCT00044031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT Immunogen
Study: NCT03426267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDN-037
Description: twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily